Review of the epidemiology of overactive bladder

Renu S Eapen, Sidney B Radomski, Renu S Eapen, Sidney B Radomski

Abstract

Overactive bladder (OAB) is common in both men and women. It is a symptom complex that causes significant detriment to quality of life in patients. Although the prevalence of OAB is similar in both sexes, there are sex-specific differences in individual symptoms and the impact on quality of life. The coexistence of benign prostatic hyperplasia with OAB can worsen quality of life in men. This review examines the major studies that looked at the epidemiology of OAB as it relates to both sexes. It focuses on both the overall prevalence rates and the incidence of individual symptoms. This paper also addresses the level of bother and quality of life in men and women with OAB. In addition, the relationship between OAB and benign prostatic hyperplasia is reviewed.

Keywords: BPH; LUTS; overactive bladder; prevalence; quality of life; sex.

References

    1. Herschorn S, Kaplan SA, Sun F, Ntanios F. Do patient characteristics predict responsiveness to treatment of overactive bladder with antimuscarinic agents? Urology. 2014;83(5):1023–1029.
    1. Valentini FA, Marti BG, Robain G. Idiopathic and neurogenic detrusor overactivity: do the different patterns have urodynamic characteristics related to gender or neurological condition? Int Braz J Urol. 2013;39(5):663–670.
    1. Link CL, Steers WD, Kusek JW, McKinlay JB. The association of adiposity and overactive bladder appears to differ by gender: results from the Boston Area Community Health survey. J Urol. 2011;185(3):955–963.
    1. Patra PB, Patra S. Sex differences in the physiology and pharmacology of the lower urinary tract. Curr Urol. 2013;6(4):179–188.
    1. Coyne KS, Sexton CC, Vats V, Thompson C, Kopp ZS, Milsom I. National community prevalence of overactive bladder in the United States stratified by sex and age. Urology. 2011;77(5):1081–1087.
    1. Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50(6):1306–1315.
    1. Irwin DE, Abrams P, Milsom I, Kopp Z, Reilly K, EPIC Study Group Understanding the elements of overactive bladder: questions raised by the EPIC study. BJU Int. 2008;101(11):1381–1387.
    1. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327–336.
    1. Milsom I, Abrams P, Cardozo L, Roberts RG, Thüroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population based prevalence study. BJU Int. 2001;87(9):760–766.
    1. Sekido N, Hinotsu S, Kawai K, Shimazui T, Akaza H. How many uncomplicated male and female overactive bladder patients reveal detrusor over-activity during urodynamic study? Int J Urol. 2006;13(10):1276–1279.
    1. Teloken C, Caraver F, Weber FA, et al. Overactive bladder: prevalence and implications in Brazil. Eur Urol. 2006;49(6):1087–1092.
    1. Temml C, Heidler S, Ponholzer A, Madersbacher S. Prevalence of the overactive bladder syndrome by applying the International Continence Society definition. Eur Urol. 2005;48(4):622–627.
    1. Nitti VW, Rosenberg S, Mitcheson DH, He W, Fakhoury A, Martin NE. Urodynamics and safety of the β3-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction. J Urol. 2013;190(4):1320–1327.
    1. Lee JY, Kim HW, Lee SJ, Koh JS, Suh HJ, Chancellor MB. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int. 2004;94(6):817–820.
    1. Kaplan SA, Roehrborn CG, Gong J, Sun F, Guan Z. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms. BJU Int. 2012;109(12):1831–1840.
    1. Vuichoud C, Loughlin K. Benign prostatic hyperplasia: epidemiology, economics and evaluation. Can J Urol. 2015;22(suppl 1):1–6.
    1. Chapple CR, Herschorn S, Abrams P, Wang JT, Brodsky M, Guan Z. Efficacy and safety of tolterodine extended-release in men with overactive bladder symptoms treated with an α-blocker: effect of baseline prostate-specific antigen concentration. BJU Int. 2010;106(9):1332–1338.
    1. Abrams P, Kaplan S, De KoningGans HJ, Millard R. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol. 2006;175(3 Pt 1):999–1004. discussion 1004.
    1. de Nunzio C, Franco G, Rocchegiani A, Iori F, Leonardo C, Laurenti C. The evolution of detrusor overactivity after watchful waiting, medical therapy and surgery in patients with bladder outlet obstruction. J Urol. 2003;169(2):535–539.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner